Heart failure. I24.8
Conditions
Interventions
Intervention 1: Intervention group 1: Receiving growth hormone a dose of 5 mg, every other day for 3 months through subcutaneous injection. Intervention 2: Control group : Receiving placebo.
Treatment - Drugs
Placebo
Intervention group 1: Receiving growth hormone a dose of 5 mg, every other day for 3 months through subcutaneous injection
Control group : Receiving placebo
Sponsors
Vice chancellor for research, School of Medicine, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Male; first-time MI; Ejection Fraction (EF) < 45% at discharge. Exclusion criteria: Patients with insulin-dependent diabetes mellitus (IDDM); Failure to control blood pressure (BP) in patients within 4 weeks after discharge from hospital; History of pulmonary disease other than asthma; Known chronic hepatic disease; Cr=2.5 or GFR=60; Systemic disease of all types; History of active infection or intake of antibiotics after discharge from hospital; HIV positive; Intake of corticosteroids within the last 4 weeks; Regularly intake of alcohol within 4 weeks after discharge. 11. Any history or evidence from examination for malignant condition 12. Any history indicating malignant condition in patient or his/her first degree relatives 13. Any blood problems (even iron deficiency or anemia) 14. Any skeletal (bone) problems (except osteoporosis) 15. any history of peripheral vascular disease (PVD) 16. Any evidence of severe (Aortic) Valve Stenosis or heart valve failure 17. Any severe valve failure 18. Moderate and severe ventricular hypertrophy 19. Any type of heart block 20. Retinopathy for any reason 21. Any type of thyroid disorder
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection Fraction (EF). Timepoint: Immediately after injection, and three months later. Method of measurement: 3-Dimentional Echocardiography.;Ventricular septum and left ventricular wall thickness. Timepoint: Immediately after injection, and three months later. Method of measurement: 2-Dimentional Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Sadeghi MD
Isfahan Cardiovascular Research Institute
Outcome results
None listed